Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Travere Therapeutics, Inc (TVTX)  
$6.30 0.30 (4.55%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 87,619,000
Market Cap: 552.00(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $5.26 - $19.34
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  993
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Travere Therapeutics is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with kidney, liver, and metabolic diseases. Co.'s approved products include: Thiola and Thiola EC (tiopronin), which are approved for the treatment of cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones; and Cholbam (cholic acid capsules), which is approved for the treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 54 59,539 71,172 111,162
Total Sell Value $364 $522,023 $673,181 $1,547,823
Total People Sold 1 7 7 7
Total Sell Transactions 1 16 21 44
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 515
  Page 5 of 21  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Calvin Sandra VP, Corp Controller and CAO   •       –      –    2022-01-31 4 S $26.51 $21,152 D/D (798) 36,614 19%     
   Calvin Sandra VP, Corp Controller and CAO   •       –      –    2022-01-31 4 A $0.00 $0 D/D 8,750 37,412     -
   Rote William E. Senior Vice President, R&D   •       –      –    2022-01-31 4 AS $27.40 $30,825 D/D (1,125) 45,235 -19%     
   Rote William E. Senior Vice President, R&D   •       –      –    2022-01-31 4 A $0.00 $0 D/D 9,840 46,360     -
   Clague Laura Chief Financial Officer   •       –      –    2022-01-31 4 AS $27.40 $33,921 D/D (1,238) 37,855 -19%     
   Clague Laura Chief Financial Officer   •       –      –    2022-01-31 4 A $0.00 $0 D/D 9,840 39,093     -
   Reed Elizabeth E SVP, GC & Corporate Secretary   •       –      –    2022-01-31 4 AS $27.40 $36,990 D/D (1,350) 43,788 -19%     
   Reed Elizabeth E SVP, GC & Corporate Secretary   •       –      –    2022-01-31 4 A $0.00 $0 D/D 9,840 45,138     -
   Dube Eric M Chief Executive Officer   •       •      –    2022-01-31 4 AS $27.40 $131,876 D/D (4,813) 164,745 -19%     
   Dube Eric M Chief Executive Officer   •       •      –    2022-01-31 4 A $0.00 $0 D/D 37,848 169,558     -
   Calvin Sandra VP, Corp Controller and CAO   •       –      –    2022-01-24 4 S $24.58 $22,955 D/D (934) 28,662 12%     
   Dube Eric M Chief Executive Officer   •       •      –    2022-01-24 4 AS $24.98 $196,668 D/D (7,873) 131,710 -12%     
   Rote William E. Senior Vice President, R&D   •       –      –    2022-01-24 4 AS $24.98 $46,838 D/D (1,875) 36,520 -12%     
   Clague Laura Chief Financial Officer   •       –      –    2022-01-24 4 AS $24.98 $51,534 D/D (2,063) 29,253 -12%     
   Reed Elizabeth E SVP, GC & Corporate Secretary   •       –      –    2022-01-24 4 AS $24.98 $56,205 D/D (2,250) 35,298 -12%     
   Heerma Peter Chief Commercial Officer   •       –      –    2022-01-24 4 AS $24.98 $46,838 D/D (1,875) 58,582 -12%     
   Reed Elizabeth E SVP, GC & Corporate Secretary   •       –      –    2022-01-11 4 AS $27.40 $137,000 D/D (5,000) 37,548 -13%     
   Clague Laura Chief Financial Officer   •       –      –    2022-01-11 4 AS $27.40 $205,500 D/D (7,500) 31,316 -13%     
   Rote William E. Senior Vice President, R&D   •       –      –    2022-01-11 4 AS $27.40 $68,500 D/D (2,500) 38,395 -13%     
   Reed Elizabeth E SVP, GC & Corporate Secretary   •       –      –    2022-01-10 4 A $0.00 $0 D/D 5,000 42,548     -
   Clague Laura Chief Financial Officer   •       –      –    2022-01-10 4 A $0.00 $0 D/D 7,500 38,816     -
   Rote William E. Senior Vice President, R&D   •       –      –    2022-01-10 4 A $0.00 $0 D/D 5,000 40,895     -
   Dube Eric M Chief Executive Officer   •       •      –    2022-01-05 4 AS $29.84 $374,369 D/D (12,500) 139,583 -20%     
   Dube Eric M Chief Executive Officer   •       •      –    2022-01-04 4 AS $30.43 $147,038 D/D (4,832) 152,083 -27%     
   Inrig Jula Chief Medical Officer   •       –      –    2022-01-01 4 A $0.00 $0 D/D 20,000 20,000     -
  515 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 5 of 21
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us